Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age | Attention Deficit/Hyperactivity Disorders | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Reutfors  J, Cesta  CE, Cohen  JM,  et al.  Antipsychotic drug use in pregnancy: a multinational study from ten countries.   Schizophr Res. 2020;220(220):106-115. doi:10.1016/j.schres.2020.03.048 PubMedGoogle Scholar
2.
Lao  KSJ, Tam  AWY, Wong  ICK,  et al.  Prescribing trends and indications of antipsychotic medication in Hong Kong from 2004 to 2014: general and vulnerable patient groups.   Pharmacoepidemiol Drug Saf. 2017;26(11):1387-1394. doi:10.1002/pds.4244 PubMedGoogle ScholarCrossref
3.
Boukhris  T, Sheehy  O, Mottron  L, Bérard  A.  Antidepressant use during pregnancy and the risk of autism spectrum disorder in children.   JAMA Pediatr. 2016;170(2):117-124. doi:10.1001/jamapediatrics.2015.3356 PubMedGoogle ScholarCrossref
4.
Croen  LA, Grether  JK, Yoshida  CK, Odouli  R, Hendrick  V.  Antidepressant use during pregnancy and childhood autism spectrum disorders.   Arch Gen Psychiatry. 2011;68(11):1104-1112. doi:10.1001/archgenpsychiatry.2011.73 PubMedGoogle ScholarCrossref
5.
Clements  CC, Castro  VM, Blumenthal  SR,  et al.  Prenatal antidepressant exposure is associated with risk for attention-deficit hyperactivity disorder but not autism spectrum disorder in a large health system.   Mol Psychiatry. 2015;20(6):727-734. doi:10.1038/mp.2014.90 PubMedGoogle ScholarCrossref
6.
Huang  H, Coleman  S, Bridge  JA, Yonkers  K, Katon  W.  A meta-analysis of the relationship between antidepressant use in pregnancy and the risk of preterm birth and low birth weight.   Gen Hosp Psychiatry. 2014;36(1):13-18. doi:10.1016/j.genhosppsych.2013.08.002 PubMedGoogle ScholarCrossref
7.
Man  KKC, Chan  EW, Ip  P,  et al.  Prenatal antidepressant use and risk of attention-deficit/hyperactivity disorder in offspring: population based cohort study.   BMJ. 2017;357:j2350. doi:10.1136/bmj.j2350PubMedGoogle Scholar
8.
Sujan  AC, Rickert  ME, Öberg  AS,  et al.  Associations of maternal antidepressant use during the first trimester of pregnancy with preterm birth, small for gestational age, autism spectrum disorder, and attention-deficit/hyperactivity disorder in offspring.   JAMA. 2017;317(15):1553-1562. doi:10.1001/jama.2017.3413 PubMedGoogle ScholarCrossref
9.
Lichtenstein  P, Carlström  E, Råstam  M, Gillberg  C, Anckarsäter  H.  The genetics of autism spectrum disorders and related neuropsychiatric disorders in childhood.   Am J Psychiatry. 2010;167(11):1357-1363. doi:10.1176/appi.ajp.2010.10020223 PubMedGoogle ScholarCrossref
10.
Petersen  I, McCrea  RL, Sammon  CJ,  et al.  Risks and benefits of psychotropic medication in pregnancy: cohort studies based on UK electronic primary care health records.   Health Technol Assess. 2016;20(23):1-176. doi:10.3310/hta20230 PubMedGoogle ScholarCrossref
11.
Baughman  FA  Jr.  Diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder.   Pediatrics. 2001;107(5):1239-1239. doi:10.1542/peds.107.5.1239 PubMedGoogle ScholarCrossref
12.
Coughlin  CG, Blackwell  KA, Bartley  C, Hay  M, Yonkers  KA, Bloch  MH.  Obstetric and neonatal outcomes after antipsychotic medication exposure in pregnancy.   Obstet Gynecol. 2015;125(5):1224-1235. doi:10.1097/AOG.0000000000000759 PubMedGoogle ScholarCrossref
13.
Vigod  SN, Gomes  T, Wilton  AS, Taylor  VH, Ray  JG.  Antipsychotic drug use in pregnancy: high dimensional, propensity matched, population based cohort study.   BMJ. 2015;350:h2298. doi:10.1136/bmj.h2298PubMedGoogle ScholarCrossref
14.
Wang  Z, Ho  PWH, Choy  MTH, Wong  ICK, Brauer  R, Man  KKC.  Advances in epidemiological methods and utilisation of large databases: a methodological review of observational studies on central nervous system drug use in pregnancy and central nervous system outcomes in children.   Drug Saf. 2019;42(4):499-513. doi:10.1007/s40264-018-0755-y PubMedGoogle ScholarCrossref
15.
Hong Kong Hospital Authority. Introduction, caring for our community’s health. Accessed November 5, 2019. https://www.ha.org.hk/visitor/ha_visitor_index.asp?Parent_ID=10004&Content_ID=10008&Ver=HTML
16.
Lau  WC, Chan  EW, Cheung  C-L,  et al.  Association between dabigatran vs warfarin and risk of osteoporotic fractures among patients with nonvalvular atrial fibrillation.   JAMA. 2017;317(11):1151-1158. doi:10.1001/jama.2017.1363 PubMedGoogle ScholarCrossref
17.
Lau  WCY, Cheung  C-L, Man  KKC,  et al.  Association between treatment with apixaban, dabigatran, rivaroxaban, or warfarin and risk for osteoporotic fractures among patients with atrial fibrillation: a population-based cohort study.   Ann Intern Med. 2020;173(1):1-9. doi:10.7326/M19-3671 PubMedGoogle ScholarCrossref
18.
Man  KKC, Lau  WCY, Coghill  D,  et al.  Association between methylphenidate treatment and risk of seizure: a population-based, self-controlled case-series study.   Lancet Child Adolesc Health. 2020;4(6):435-443. doi:10.1016/S2352-4642(20)30100-0 PubMedGoogle ScholarCrossref
19.
Raman  SR, Man  KKC, Bahmanyar  S,  et al.  Trends in attention-deficit hyperactivity disorder medication use: a retrospective observational study using population-based databases.   Lancet Psychiatry. 2018;5(10):824-835. doi:10.1016/S2215-0366(18)30293-1 PubMedGoogle ScholarCrossref
20.
Lee  PA, Chernausek  SD, Hokken-Koelega  AC, Czernichow  P; International Small for Gestational Age Advisory Board.  International Small for Gestational Age Advisory Board consensus development conference statement: management of short children born small for gestational age, April 24-October 1, 2001.   Pediatrics. 2003;111(6 Pt 1):1253-1261. doi:10.1542/peds.111.6.1253 PubMedGoogle Scholar
21.
Cheung  KK, Wong  IC, Ip  P,  et al.  Experiences of adolescents and young adults with ADHD in Hong Kong: treatment services and clinical management.   BMC Psychiatry. 2015;15(1):95. doi:10.1186/s12888-015-0478-x PubMedGoogle ScholarCrossref
22.
Desai  RJ, Rothman  KJ, Bateman  BT, Hernandez-Diaz  S, Huybrechts  KF.  A propensity-score–based fine stratification approach for confounding adjustment when exposure is infrequent.   Epidemiology. 2017;28(2):249-257. doi:10.1097/EDE.0000000000000595 PubMedGoogle ScholarCrossref
23.
Webster-Clark  M, Stürmer  T, Wang  T,  et al.  Using propensity scores to estimate effects of treatment initiation decisions: State of the science.   Stat Med. 2021;40(7):1718-1735. doi:10.1002/sim.8866 PubMedGoogle ScholarCrossref
24.
Desai  RJ, Franklin  JM.  Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.   BMJ. 2019;367:l5657. doi:10.1136/bmj.l5657PubMedGoogle Scholar
25.
Daniels  JL, Forssen  U, Hultman  CM,  et al.  Parental psychiatric disorders associated with autism spectrum disorders in the offspring.   Pediatrics. 2008;121(5):e1357-e1362. doi:10.1542/peds.2007-2296 PubMedGoogle ScholarCrossref
26.
Leung  GM, Tin  KY, O’Donnell  O.  Redistribution or horizontal equity in Hong Kong’s mixed public-private health system: a policy conundrum.   Health Econ. 2009;18(1):37-54. doi:10.1002/hec.1342 PubMedGoogle ScholarCrossref
27.
Valenstein  M, Blow  FC, Copeland  LA,  et al.  Poor antipsychotic adherence among patients with schizophrenia: medication and patient factors.   Schizophr Bull. 2004;30(2):255-264. doi:10.1093/oxfordjournals.schbul.a007076 PubMedGoogle ScholarCrossref
28.
Wang  Z, Brauer  R, Man  KKC, Alfageh  B, Mongkhon  P, Wong  ICK.  Prenatal exposure to antipsychotic agents and the risk of congenital malformations in children: a systematic review and meta-analysis.   Br J Clin Pharmacol. 2021. doi:10.1111/bcp.14839 PubMedGoogle Scholar
29.
Gauderman  WJ, Witte  JS, Thomas  DC.  Family-based association studies.   J Natl Cancer Inst Monogr. 1999;1999(26):31-37. doi:10.1093/oxfordjournals.jncimonographs.a024223 PubMedGoogle ScholarCrossref
Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    Original Investigation
    August 16, 2021

    Association Between Prenatal Exposure to Antipsychotics and Attention-Deficit/Hyperactivity Disorder, Autism Spectrum Disorder, Preterm Birth, and Small for Gestational Age

    Author Affiliations
    • 1Research Department of Practice and Policy, UCL School of Pharmacy, London, England
    • 2Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China
    • 3Laboratory of Data Discovery for Health, Hong Kong Science Park, Hong Kong Special Administrative Region, China
    • 4Groningen Research Institute of Pharmacy, Unit of PharmacoTherapy, Epidemiology and Economics, University of Groningen, Groningen, the Netherlands
    • 5Department of Paediatrics and Psychiatry, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia
    • 6Murdoch Children’s Research Institute, Melbourne, Australia
    • 7Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China
    • 8Department of Child and Adolescent Psychiatry, King’s College London, Institute of Psychiatry, Psychology and Neuroscience, London, England
    JAMA Intern Med. 2021;181(10):1332-1340. doi:10.1001/jamainternmed.2021.4571
    Key Points

    Question  Does prenatal exposure to antipsychotics increase the risk of preterm birth, small for gestational age, attention-deficit/hyperactivity disorder (ADHD), or autism spectrum disorder (ASD)?

    Findings  In this cohort study of 411 251 mother-child pairs, there was not an increased risk of ADHD, ASD, preterm birth, and small for gestational age with prenatal use of antipsychotics. Maternal psychiatric disorders were associated with a significantly increased risk of ADHD and ASD, but not with preterm birth or small for gestational age in neonates.

    Meaning  The findings of this study suggest that there is no association between prenatal exposure to antipsychotics and ADHD, ASD, preterm birth, and small for gestational age; however, underlying maternal psychiatric disorders may be associated with the risk of ADHD and ASD in children.

    Abstract

    Importance  The risk of birth and neurodevelopmental complications with prenatal exposure to antipsychotics is unclear.

    Objective  To evaluate the association between prenatal antipsychotics exposure and the risk of birth and neurodevelopmental problems.

    Design, Setting, and Participants  This population-based cohort study included children born between January 2001 and January 2015 with follow-up to December 2019 who were identified by the Hong Kong Clinical Data Analysis and Reporting System. Pregnancies with maternal antidepressant/lithium exposure were removed. Primary analyses compared gestationally exposed and gestationally nonexposed individuals with propensity score fine stratification. Additional analyses included gestationally exposed individuals vs those with past exposure and a sibling-matched analysis to evaluate the effect of confounding by indication.

    Exposures  Prenatal antipsychotic exposure.

    Main Outcomes and Measures  Preterm birth (<37 gestational weeks), small for gestational age (birth weight <2 standard deviations below the mean for gestational age), and first diagnosis of attention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) in children.

    Results  The cohorts included 333 749 mother-child pairs for ADHD (mean [SD] maternal age at delivery, 31.46 [5.03] years) and 411 251 pairs for ASD, preterm birth, and small for gestational age analyses (mean [SD] maternal age at delivery, 31.56 [5.01] years). There were 13 196 children (3.95%) with a diagnosis of ADHD, 8715 (2.12%) with ASD, 33 891 (8.24%) preterm, and 7009 (1.70%) who were small for gestational age. The weighted hazard ratio (wHR) was 1.16 (95% CI, 0.83-1.61) for ADHD and 1.06 (95% CI, 0.70-1.60) for ASD, while the weighted odds ratio (wOR) was 1.40 (95% CI, 1.13-1.75) for preterm birth and 1.36 (95% CI, 0.86-2.14) for small for gestational age when comparing gestationally exposed with gestationally nonexposed individuals. Additional analyses showed no association when comparing gestationally exposed individuals with those with past exposure (ADHD: wHR, 0.99; 95% CI, 0.60-1.61; ASD: wHR, 1.10; 95% CI, 0.58-2.08; preterm birth: wOR, 0.93; 95% CI, 0.70-1.24; small for gestational age: wOR, 1.21; 95% CI, 0.66-2.20) and in a sibling-matched analysis (ADHD: wHR, 0.41; 95% CI, 0.04-4.93; ASD: wHR, 0.90; 95% CI, 0.40-2.01; preterm birth: wOR, 1.25; 95% CI, 0.85-1.82; small for gestational age: wOR, 0.86, 95% CI, 0.32-2.31).

    Conclusions and Relevance  In this cohort study, the findings did not suggest that prenatal antipsychotics exposure increased the risk of ADHD, ASD, or small for gestational age. In the primary analysis, there was a small increased risk of preterm birth, but additional analyses comparing gestationally exposed individuals with those with past exposure and comparing gestationally exposed with gestationally nonexposed siblings did not support an increased risk. Given the benefits of treating psychosis during pregnancy, our findings do not support a recommendation for women to discontinue receipt of their regular antipsychotic treatment during pregnancy.

    ×